Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population.
Sign Up to like & getrecommendations! Published in 2023 at "Brain and behavior"
DOI: 10.1002/brb3.2799
Abstract: BACKGROUND Galcanezumab is a monoclonal antibody acting against the calcitonin gene-related peptide approved for the preventive treatment of migraine. The aim of this article is to explore its effectiveness and safety of galcanezumab in chronic… read more here.
Keywords: headache; migraine; chronic migraine; migraine medication ... See more keywords
Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review
Sign Up to like & getrecommendations! Published in 2022 at "Headache"
DOI: 10.1111/head.14415
Abstract: Along with the development of novel migraine therapies as the monoclonal antibodies against calcitonin gene‐related peptide (CGRP) and its receptor, the question arises if the treatment of chronic migraine (CM) and medication overuse headache (MOH)… read more here.
Keywords: headache; cgrp; medication overuse; chronic migraine ... See more keywords
Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial
Sign Up to like & getrecommendations! Published in 2021 at "Cephalalgia"
DOI: 10.1177/03331024211006903
Abstract: Objective “Pain interference” and “headache impact” refer to negative consequences that pain and headache have on one’s life. This study investigated determinants of these negative impacts in a large patient cohort who have chronic migraine… read more here.
Keywords: medication overuse; headache impact; chronic migraine; migraine medication ... See more keywords